Christian A Lerchenmüller

Suggest Changes
Learn More
BACKGROUND Cetuximab and bevacizumab have both been shown to improve outcomes in patients with metastatic colorectal cancer when added to chemotherapy regimens; however, their comparative(More)
BACKGROUND The definition of a best maintenance strategy following combination chemotherapy plus bevacizumab in metastatic colorectal cancer is unclear. We investigated whether no continuation of(More)
BACKGROUND FIRE-3 compared first-line 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus cetuximab with FOLFIRI plus bevacizumab in patients with KRAS exon 2 wild-type metastatic colorectal(More)
BACKGROUND Understanding how to sequence targeted therapies for metastatic renal cell carcinoma (mRCC) is important for maximisation of clinical benefit. OBJECTIVES To prospectively evaluate(More)
S. Hegewisch-Becker1, U. Graeven2, C. Lerchenmüller3, B. Killing4, R. Depenbusch5, C. Steffens6, S. Al-Batran7, T. Lange8, G. Dietrich9, J. Stoehlmacher10, A. Tannapfel11, A. Reinacher-Schick12, J.(More)
PURPOSE We investigated choice and efficacy of subsequent treatment, with special focus on second-line therapy, in the FIRE-3 trial (FOLFIRI plus cetuximab [arm A] or bevacizumab [arm B]) for(More)